Women's imaging vendor Fischer Imaging of Denver has entered into a deal to sell the intellectual property of its mammography business and products to Hologic of Bedford, MA, for $32 million.
The deal includes Fischer's flagship SenoScan full-field digital mammography (FFDM) system, as well as the company's MammoTest stereotactic breast biopsy system.
Hologic also agreed to extend Fischer a $5 million secured loan as part of the deal, with the amount credited toward the $32 million purchase price if the agreement is executed. The acquisition is expected to close in 90-120 days, according to Hologic.
Fischer recently announced that it was facing liquidity issues and was taking steps to investigate strategic alternatives. Fischer president and CEO Harris Ravine called the deal a "difficult decision" but said the agreement would allow the company to pay outstanding obligations and to explore strategic alternatives for its radiology, electrophysiology, and surgical businesses.
Fischer would continue to service and support the installed base of SenoScan and MammoTest systems, and maintain its existing contractual obligations for providing SenoScan and MammoTest systems to Philips Medical Systems and Ethicon Endo-Surgery, respectively.
By AuntMinnie.com staff writers
June 23, 2005
Related Reading
Fischer names COO, June 3, 2005
Fischer posts mixed Q1, May 23, 2005
Fischer late with 10-Q report, May 17, 2005
Fischer's 2004 net loss narrows on higher sales, April 1, 2005
Fischer nets SenoScan installs, December 9, 2004
Copyright © 2005 AuntMinnie.com
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
